Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Wells, Athol UBehr, Juergen
Costabel, Ulrich
Cottin, Vincent
Poletti, Venerino
Richeldi, Luca
Gudmundsson, Gunnar
Issue Date
2012-11
Metadata
Show full item recordCitation
Thorax 2012, 67(11):938-40Description
To access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.Additional Links
http://dx.doi.org/10.1136/thoraxjnl-2012-202580http://thorax.bmj.com/content/67/11/938
Rights
Archived with thanks to Thoraxae974a485f413a2113503eed53cd6c53
10.1136/thoraxjnl-2012-202580
Scopus Count
Collections
Related articles
- Challenges in idiopathic pulmonary fibrosis trials: the point on end-points.
- Authors: Albera C
- Issue date: 2011 Sep 1
- Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials.
- Authors: du Bois RM, Nathan SD, Richeldi L, Schwarz MI, Noble PW
- Issue date: 2012 Oct 15
- A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer.
- Authors: Vancheri C, du Bois RM
- Issue date: 2013 Feb
- The European IPF Network: towards better care for a dreadful disease.
- Authors: Guenther A, European IPF Network.
- Issue date: 2011 Apr
- Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.
- Authors: Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK
- Issue date: 2012 May 15